Following swift approval from the FDA, Amgen Inc. expects its next blockbuster drug for chemotherapy patients to enter the market April 1. (BioWorld Today)
Following swift approval from the FDA, Amgen Inc. expects its next blockbuster drug for chemotherapy patients to enter the market April 1. (BioWorld Today)
One year after signing a $1.4 billion agreement aimed at developing 12 drugs in obesity and diabetes, CuraGen Corp. and partner Bayer Corp. said they have successfully completed screening against four targets. (BioWorld Today)
One year after signing a $1.4 billion agreement aimed at developing 12 drugs in obesity and diabetes, CuraGen Corp. and partner Bayer Corp. said they have successfully completed screening against four targets. (BioWorld Today)
Amylin Pharmaceuticals Inc. started the second of three Phase III trials on AC2993, a compound designed to treat people with Type II diabetes by improving glucose control. (BioWorld Today)
Amylin Pharmaceuticals Inc. started the second of three Phase III trials on AC2993, a compound designed to treat people with Type II diabetes by improving glucose control. (BioWorld Today)
DeCode Genetics Inc. and Roche Holdings SA signed a three-year alliance to discover and develop therapeutics based on the achievements of a previous gene discovery collaboration between the companies. (BioWorld Today)
DeCode Genetics Inc. and Roche Holdings SA signed a three-year alliance to discover and develop therapeutics based on the achievements of a previous gene discovery collaboration between the companies. (BioWorld Today)
